Stockreport

Albireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary Atresia

Albireo Pharma, Inc.  (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
PDF Expands A4250 development potential in rare cholestatic liver diseases Biliary atresia is among the most common rare pediatric liver diseases and is the most common ped [Read more]